External analyst notes, journalism, and industry commentary cited with attribution.
Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Rexlemestrocel-L's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Rexlemestrocel-L. Showing past 6 months and next 12 months · 11 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Rexlemestrocel-L | Mesoblast | Mesenchymal Stem Cell | Phase 3 | 0 | ||||
| Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil | Kumamoto University | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Acetazolamide Per os for Decompensation of Heart Failure | Samara State Medical University | — | Phase 4 | — | — | — | — | — |
| Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation | Dongying Zhang | — | Phase 4 | — | — | — | — | — |
| Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure | Evi Liliek Wulandari | — | Phase 4 | — | — | — | — | — |
| Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure | Raffaele De Caterina | — | Phase 4 | — | — | — | — | — |
| The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF | University Clinical Hospital Mostar | — | Phase 4 | — | — | — | — | — |
| Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II | Fazaia Ruth Pfau Medical College | — | Phase 4 | — | — | — | — | — |
| The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency | China-Japan Friendship Hospital | — | Phase 4 | — | — | — | — | — |
| Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | — | Phase 4 | — | — | — | — | — |
| The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF) | Tomsk National Research Medical Center of the Russian Academy of Sciences | — | Phase 4 | — | — | — | — | — |
| Qishenyiqi for Ventricular Remodeling After Myocardial Infarction | Qilu Hospital of Shandong University | — | Phase 4 | — | — | — | — | — |
| The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis | Nicholas Carlson | — | Phase 4 | — | — | — | — | — |
| Allograft Dysfunction in Heart Transplant | Paul Kim | — | Phase 4 | — | — | — | — | — |
| Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device | Columbia University | — | Phase 4 | — | — | — | — | — |
| Vericiguat and Reverse Remodeling Indices in Heart Failure | University Medical Centre Ljubljana | — | Phase 4 | — | — | — | — | — |
| Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease | National Taiwan University Hospital | — | Phase 4 | — | — | — | — | — |
| EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease | National Taiwan University Hospital | — | Phase 4 | — | — | — | — | — |
| Metoprolol in Patients With HFrEF and COPD | Xiangya Hospital of Central South University | — | Phase 4 | — | — | — | — | — |
| A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record | Herlev and Gentofte Hospital | — | Phase 4 | — | — | — | — | — |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | AstraZeneca | — | Phase 4 | — | — | — | — | — |
| Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score | Boston Children's Hospital | — | Phase 3 | — | — | — | — | — |
| S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction | Shenzhen People's Hospital | — | Phase 3 | — | — | — | — | — |
| CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine | Niguarda Hospital | — | Phase 3 | — | — | — | — | — |
| A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | Fundación para la Investigación del Hospital Clínico de Valencia | — | Phase 3 | — | — | — | — | — |
| The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction | John Paul II Hospital, Krakow | — | Phase 3 | — | — | — | — | — |
| The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | University Medical Center Groningen | — | Phase 3 | — | — | — | — | — |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Cytokinetics | — | Phase 3 | — | — | — | — | — |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | X4 Pharmaceuticals | — | Phase 3 | — | — | — | — | — |
| Outpatient Hypertonic Saline and Loop Diuretic Combination Therapy in Cardiorenal | University of Monastir | — | Phase 3 | — | — | — | — | — |
| Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure | Pharmacosmos A/S | — | Phase 3 | — | — | — | — | — |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Alessandro Doria | — | Phase 3 | — | — | — | — | — |
| Dapagliflozin for Cardio-renal Protection After ICU Discharge | Assistance Publique - Hôpitaux de Paris | — | Phase 3 | — | — | — | — | — |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Eli Lilly and Company | — | Phase 3 | — | — | — | — | — |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Boehringer Ingelheim | — | Phase 3 | — | — | — | — | — |
| Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction. | Tongji Hospital | — | Phase 3 | — | — | — | — | — |
| Communication During Hospitalization About Resuscitation Trial | University of Vermont | — | PHASE2/PHASE3 | — | — | — | — | — |
| Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure | Jens D Hove, MD,PHD | — | PHASE2/PHASE3 | — | — | — | — | — |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | CSL Behring | — | PHASE2/PHASE3 | — | — | — | — | — |
| Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate. | Ralf Rothoerl | — | Phase 2 | — | — | — | — | — |
| Ertugliflozin in Chronic Heart Failure | Yale University | — | Phase 2 | — | — | — | — | — |
| Study of JK07 in Patients With Chronic Heart Failure | Salubris Biotherapeutics Inc | — | Phase 2 | — | — | — | — | — |
| Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction | Akros Pharma Inc. | — | Phase 2 | — | — | — | — | — |
| Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study | Maximo Agustin Schiavone | — | Phase 2 | — | — | — | — | — |
| Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation | University of Texas Southwestern Medical Center | — | Phase 2 | — | — | — | — | — |
| Endocalyx for Heart Failure | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — | Phase 2 | — | — | — | — | — |
| Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure | Tasly Pharmaceutical Group Co., Ltd | — | Phase 2 | — | — | — | — | — |
| Swedish Cardiac And Renal Failure Study-1 | Karolinska Institutet | — | Phase 2 | — | — | — | — | — |
| Chronic Exogenous Ketosis in HFpEF | Duke University | — | Phase 2 | — | — | — | — | — |
| Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR) | Nantes University Hospital | — | Phase 2 | — | — | — | — | — |
| Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) | University Medical Center Groningen | — | Phase 2 | — | — | — | — | — |